KR20070015517A - 요오드화된 단량체 및 이량체의 혼합물을 포함하는 ｘ-선조영제 제형 - Google Patents
요오드화된 단량체 및 이량체의 혼합물을 포함하는 ｘ-선조영제 제형 Download PDFInfo
- Publication number
- KR20070015517A KR20070015517A KR1020067018308A KR20067018308A KR20070015517A KR 20070015517 A KR20070015517 A KR 20070015517A KR 1020067018308 A KR1020067018308 A KR 1020067018308A KR 20067018308 A KR20067018308 A KR 20067018308A KR 20070015517 A KR20070015517 A KR 20070015517A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- hydroxy
- independently
- moiety
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 109
- 239000000539 dimer Substances 0.000 title claims abstract description 44
- 239000000178 monomer Substances 0.000 title claims abstract description 37
- 238000009472 formulation Methods 0.000 title abstract description 37
- 239000002872 contrast media Substances 0.000 claims abstract description 52
- -1 triiodo-substituted benzene Chemical class 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000002285 radioactive effect Effects 0.000 claims abstract description 11
- 238000012800 visualization Methods 0.000 claims abstract description 8
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 22
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 15
- DLPPIGPJCKKVBA-UHFFFAOYSA-N Iosimenol Chemical group OCC(O)CNC(=O)C1=C(I)C(C(=O)N)=C(I)C(N(CC(O)CO)C(=O)CC(=O)N(CC(O)CO)C=2C(=C(C(=O)NCC(O)CO)C(I)=C(C(N)=O)C=2I)I)=C1I DLPPIGPJCKKVBA-UHFFFAOYSA-N 0.000 claims description 13
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 13
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 13
- 229960004537 ioversol Drugs 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 229960004647 iopamidol Drugs 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 238000002059 diagnostic imaging Methods 0.000 claims description 4
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical group OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 claims description 4
- IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002603 iopromide Drugs 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 235000021317 phosphate Nutrition 0.000 claims description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000012062 aqueous buffer Substances 0.000 claims description 3
- 229960000780 iomeprol Drugs 0.000 claims description 3
- 229960000824 iopentol Drugs 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000008227 sterile water for injection Substances 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000002961 echo contrast media Substances 0.000 claims 1
- GKODZWOPPOTFGA-UHFFFAOYSA-N tris(hydroxyethyl)aminomethane Chemical compound OCCC(N)(CCO)CCO GKODZWOPPOTFGA-UHFFFAOYSA-N 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229910052740 iodine Inorganic materials 0.000 description 11
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 11
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000011630 iodine Substances 0.000 description 10
- 229950004246 iosimenol Drugs 0.000 description 9
- 229960001025 iohexol Drugs 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 6
- 150000003858 primary carboxamides Chemical group 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 238000002583 angiography Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229940095629 edetate calcium disodium Drugs 0.000 description 5
- 229960000281 trometamol Drugs 0.000 description 5
- ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical class OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229940039231 contrast media Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- RIWAPWDHHMWTRA-UHFFFAOYSA-N 1,2,3-triiodobenzene Chemical compound IC1=CC=CC(I)=C1I RIWAPWDHHMWTRA-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 0 *c1cc([*-])cc(O)c1 Chemical compound *c1cc([*-])cc(O)c1 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 229960001482 bismuth subnitrate Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000007794 visualization technique Methods 0.000 description 2
- DGAIEPBNLOQYER-BMSJAHLVSA-N 1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-3-n-methyl-5-[[2-(trideuteriomethoxy)acetyl]amino]benzene-1,3-dicarboxamide Chemical compound [2H]C([2H])([2H])OCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-BMSJAHLVSA-N 0.000 description 1
- COFWQRPEYJADHT-UHFFFAOYSA-N 1-n,3-n-bis(2,3-dihydroxypropyl)-5-[(3-hydroxy-2-oxopropyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound OCC(O)CNC(=O)C1=C(I)C(NCC(=O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I COFWQRPEYJADHT-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- BVNRGLAAFYNAFL-UHFFFAOYSA-N C1CC[IH]C1 Chemical compound C1CC[IH]C1 BVNRGLAAFYNAFL-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- SHOKWSLXDAIZPP-UHFFFAOYSA-N [4-(4-iodooxy-2-methyl-5-propan-2-ylphenyl)-5-methyl-2-propan-2-ylphenyl] hypoiodite Chemical compound C1=C(OI)C(C(C)C)=CC(C=2C(=CC(OI)=C(C(C)C)C=2)C)=C1C SHOKWSLXDAIZPP-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 description 1
- 235000011188 calcium disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000002585 cerebral angiography Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229960005223 diatrizoic acid Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960000929 iotalamic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000007487 urography Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55224004P | 2004-03-11 | 2004-03-11 | |
| US60/552,240 | 2004-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070015517A true KR20070015517A (ko) | 2007-02-05 |
Family
ID=34964357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067018308A Withdrawn KR20070015517A (ko) | 2004-03-11 | 2005-03-11 | 요오드화된 단량체 및 이량체의 혼합물을 포함하는 ｘ-선조영제 제형 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8679460B2 (https=) |
| EP (2) | EP1725268B1 (https=) |
| JP (1) | JP2007528424A (https=) |
| KR (1) | KR20070015517A (https=) |
| CN (1) | CN1938050A (https=) |
| AT (1) | ATE529135T1 (https=) |
| AU (1) | AU2005221716A1 (https=) |
| CA (1) | CA2559628A1 (https=) |
| ES (1) | ES2374633T3 (https=) |
| IL (1) | IL177888A0 (https=) |
| NO (1) | NO20064629L (https=) |
| WO (1) | WO2005087272A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200006268A (ko) * | 2018-07-10 | 2020-01-20 | 한국원자력연구원 | 소체와 연결된 실 모양의 구조물 가시화 조성물 및 이의 가시화 방법 |
| US11185598B2 (en) | 2010-03-23 | 2021-11-30 | Ge Healthcare As | Preparation of stabilised x-ray diagnostic composition |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2240432B1 (en) * | 2008-01-14 | 2012-07-04 | Mallinckrodt LLC | Process for the preparation of iosimenol |
| US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| CN102271715A (zh) | 2009-01-09 | 2011-12-07 | 通用电气医疗集团股份有限公司 | 对比剂组合物 |
| US20130039888A1 (en) | 2011-06-08 | 2013-02-14 | Nationwide Children's Hospital Inc. | Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
| JP2013091701A (ja) | 2011-10-25 | 2013-05-16 | Dow Corning Toray Co Ltd | 硬化性組成物 |
| US9725716B2 (en) * | 2011-12-06 | 2017-08-08 | Ohio State Innovation Foundation and Research Institute at Nationwide Children's Hospital | Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease |
| CN104114190A (zh) * | 2012-01-11 | 2014-10-22 | 通用电气医疗集团股份有限公司 | 具有低碘浓度的x-射线成像造影介质和x-射线成像方法 |
| WO2013180777A1 (en) * | 2012-05-30 | 2013-12-05 | Verrow Pharmaceuticals, Inc. | Stabilized formulations containing iodinated contrast agents and cyclodextrins |
| AU2013296425B2 (en) | 2012-08-01 | 2018-06-07 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| CN112386712B (zh) * | 2020-11-09 | 2022-08-30 | 张洪 | 分子探针及其制备方法和用途 |
| CN119656340A (zh) * | 2024-12-13 | 2025-03-21 | 福安药业集团宁波天衡制药有限公司 | 一种碘佛醇注射液及其制备方法 |
| CN120899953B (zh) * | 2025-10-13 | 2025-12-12 | 浙江迪安鉴识科技有限公司 | 一种尸体用血管造影剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2511871A1 (fr) | 1981-08-28 | 1983-03-04 | Guerbet Sa | Procede pour augmenter la tolerance des produits opacifiants et produits opacifiants ainsi obtenus |
| US5698739A (en) * | 1989-07-05 | 1997-12-16 | Schering Aktiengesellschaft | Carboxamide non-ionic contrast media |
| EP0619744A4 (en) | 1991-12-03 | 1995-02-08 | Mallinckrodt Medical Inc | NON-ionic X-RAY CONTRASTS, COMPOSITIONS AND METHODS. |
| IT1256248B (it) | 1992-12-24 | 1995-11-29 | Bracco Spa | Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x |
| DE19627309C2 (de) | 1996-06-27 | 1999-07-29 | Schering Ag | Wäßrige injizierbare Formulierungen verwendbar als Kontrastmittel |
| ITMI20011706A1 (it) | 2001-08-03 | 2003-02-03 | Bracco Imaging Spa | Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic |
| US8518373B2 (en) * | 2001-08-03 | 2013-08-27 | Bracco Imaging Spa | Ionic and non-ionic radiographic contrast agents for use in combined X-ray and nuclear magnetic resonance diagnostics |
| US7250153B2 (en) * | 2002-12-12 | 2007-07-31 | Biophysica Research, Inc. | Contrast media formulations having improved biological tolerance |
-
2005
- 2005-03-11 AT AT05731581T patent/ATE529135T1/de not_active IP Right Cessation
- 2005-03-11 ES ES05731581T patent/ES2374633T3/es not_active Expired - Lifetime
- 2005-03-11 EP EP05731581A patent/EP1725268B1/en not_active Expired - Lifetime
- 2005-03-11 US US10/588,674 patent/US8679460B2/en not_active Expired - Fee Related
- 2005-03-11 JP JP2007503103A patent/JP2007528424A/ja not_active Withdrawn
- 2005-03-11 KR KR1020067018308A patent/KR20070015517A/ko not_active Withdrawn
- 2005-03-11 WO PCT/US2005/008389 patent/WO2005087272A2/en not_active Ceased
- 2005-03-11 CA CA002559628A patent/CA2559628A1/en not_active Abandoned
- 2005-03-11 EP EP10174231A patent/EP2253332B1/en not_active Expired - Lifetime
- 2005-03-11 CN CNA2005800078749A patent/CN1938050A/zh active Pending
- 2005-03-11 AU AU2005221716A patent/AU2005221716A1/en not_active Abandoned
-
2006
- 2006-09-04 IL IL177888A patent/IL177888A0/en unknown
- 2006-10-10 NO NO20064629A patent/NO20064629L/no not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11185598B2 (en) | 2010-03-23 | 2021-11-30 | Ge Healthcare As | Preparation of stabilised x-ray diagnostic composition |
| KR20200006268A (ko) * | 2018-07-10 | 2020-01-20 | 한국원자력연구원 | 소체와 연결된 실 모양의 구조물 가시화 조성물 및 이의 가시화 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2374633T3 (es) | 2012-02-20 |
| US20080317675A1 (en) | 2008-12-25 |
| EP2253332A2 (en) | 2010-11-24 |
| US8679460B2 (en) | 2014-03-25 |
| EP2253332B1 (en) | 2012-10-10 |
| WO2005087272A2 (en) | 2005-09-22 |
| EP2253332A3 (en) | 2011-03-23 |
| EP1725268A2 (en) | 2006-11-29 |
| AU2005221716A1 (en) | 2005-09-22 |
| CN1938050A (zh) | 2007-03-28 |
| NO20064629L (no) | 2006-11-28 |
| CA2559628A1 (en) | 2005-09-22 |
| WO2005087272A3 (en) | 2006-06-22 |
| JP2007528424A (ja) | 2007-10-11 |
| EP1725268B1 (en) | 2011-10-19 |
| IL177888A0 (en) | 2006-12-31 |
| ATE529135T1 (de) | 2011-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3585233B2 (ja) | レントゲン撮影造影剤としてヨウ化芳香族化合物を使用する放射線診断用注射剤水溶液 | |
| ES2486296T3 (es) | Agentes de contraste | |
| US8679460B2 (en) | Low osmolar X-ray contrast media formulations | |
| EP2606912A1 (en) | Contrast medium composition with contrast enhancement effect by comprising highly concentrated agent | |
| HU217075B (hu) | Vizes vivőközegű, nemionos kontrasztanyagot tartalmazó kontrasztközegek, és eljárás azok előállítására | |
| EP1411992A1 (en) | Ionic and non-ionic radiographic contrast agents for use in combined x-ray and nuclear magnetic resonance diagnostics | |
| ES2398291T3 (es) | Agentes de contraste | |
| US7485753B2 (en) | Contrast agents | |
| CA2509035C (en) | Contrast media formulations having improved biological tolerance | |
| EP1798219A1 (en) | Contrast agents | |
| KR20150014526A (ko) | 고농도의 조영제를 포함하여 높은 조영 증강 효과를 나타내는 조영제 조성물 | |
| Aljohani | Iodinated Contrast agents within Radiology | |
| Jascinth et al. | Contrast agents in computed tomography: A review | |
| US7662859B2 (en) | Contrast agents | |
| GB2465663A (en) | X-ray contrast agent compositions comprising an iodinated X-ray contrast agent and ethylenediamine-N,N-disuccinic acid | |
| Grainger | Development of intravascular contrast agents: the first 100 years | |
| Patil | 38 Contrast Agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060908 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |